RCT 70 hospitalized COVID-19 patients evaluating the effects of N-acetylcysteine (NAC) and melatonin on liver injury induced by remdesivir treatment. NAC 600mg twice daily and melatonin 6mg daily. All patients received remdesivir. Liver enzymes (AST, ALT, ALP) and CBC levels were measured on days 1, 3 and 6. Levels were lower in the treatment group but the differences were not statistically significant. The treatment group was older (63 vs. 55) and had more severe patients (24% vs. 8%). Authors recommend further studies with longer duration and different doses to establish if these antioxidants can reduce remdesivir hepatotoxicity.
Karimi et al., 13 Feb 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, mean age 63.4, 5 authors, trial
IRCT20210926052586N2.
Contact:
mohamdarvishii@gmail.com.
